Pfizer Limited
Pfizer Centre, Patel Estate,
Off S. V. Road, Jogeshwari (W), Mumbai 400 102
Tel 91 22 6693 2000 Fax 91 22 2678 2600

PART I

Statement of Standalone Audited Financial Results for the Quarter and Year ended 31st March, 2013

(₹ in Lakhs)

	Particulars	Quarter ended 31st March 2013	Quarter ended 31st Dec 2012	Quarter ended 31st March 2012	Year ended 31st March 2013	Year ended 31st March 2012
		Audited	Unaudited	Audited	Audited	Audited
1	Income from Operations					
	(a) Net Sales/Income from Operations (Net of excise duty)	25,219	22,978	25,174	94,798	101,732
	(b) Other Operating Income	2,955	2,726	2,090	10,209	7,596
	Total income from operations (net)	28,174	25,704	27,264	105,007	109,328
2	Expenses					
	a. Cost of materials consumed	7,885	6,175	5,977	23,849	23,077
	b. Purchases of stock-in-trade	1,653	3,065	3,827	9,723	14,681
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(170)	(1,475)	(687)	(267)	(1,849)
	d. Employee benefits expense	4,747	5,509	3,440	20,670	19,282
	e. Depreciation and amortisation expense	192	198	232	802	956
	(3 + 4)	0,000	0,000	0,000	00,000	00,000
6	Finance costs	(8)	5	35	24	59
7	Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	8,351	6,426	7,259	28,407	27,791
8	Exceptional items: (a) VRS	62	(4)	-	(442)	(38)
	(b) Gain on sale of Animal Health business	-	-	-	38,252	-
	(c) Gain on sale of Investment	-	3,160	-	3,160	-
9	Profit from ordinary activities before tax (7 + 8)	8,413	9,582	7,259	69,377	27,753
10	Tax expense	2,597	3,194	2,449	19,057	9,292
11	Net Profit from ordinary activities after tax (9 - 10)	5,816	6,388	4,810	50,320	18,461
12	Paid-up equity share capital (Face Value per share ₹ 10)	2,984	2,984	2,984	2,984	2,984
13	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year					127,485
14	Earnings per share - Basic and Diluted (of ₹ 10/- each) (not annualised)	19.49	21.41	16.12	168.63	61.87

PART II

Select Information for the Quarter and Year ended 31st March, 2013

		Quarter ended 31st March 2013	Quarter ended 31st Dec 2012	Quarter ended 31st March 2012	Year ended 31st March 2013	Year ended 31st March 2012
						Audited
A	**Promoters and Promoter Group Shareholding**					
	a) Pledged/Encumbered					
	- Number of shares	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered					
	- Number of Shares	21,113,171	21,113,171	21,113,171	21,113,171	21,113,171
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	70.75%	70.75%	70.75%	70.75%	70.75%

	Particulars	Quarter ended 31st March 2013
B	**INVESTOR COMPLAINTS**	
	Pending at the beginning of the quarter	2
	Received during the quarter	25
	Disposed of during the quarter	26
	Remaining unresolved at the end of the quarter	1

NOTES:

1. The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its meeting held on May 14, 2013 and were approved and taken on record at the meeting of the Board of Directors of the Company held on that date.

2. The financial results for year ended March 31, 2013 have been audited by the statutory auditors of the Company. The audit report on the financial results does not contain any qualifications. The Audit These financial results are being published in accordance with the Listing Agreement and are available on the Company's website
financial year and the published year to date figures up to the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter were only reviewed and not subjected to audit.

4. Discontinuing operations:

   The Company had incorporated a wholly owned subsidiary on February 10, 2012 under the name Pfizer Animal Pharma Private Limited for a temporary period with a view to spin off the animal health business of Pfizer Limited as a pre-step to subsequent sale to a wholly owned subsidiary of Pfizer Inc. in India subject to necessary approvals.

   The business operations of animal health division was transferred to the above subsidiary on April 2, 2012 by way of slump sale for a consideration of ₹42,428 lakhs. The gain of ₹38,252 lakhs on the slump sale of the said business operation was disclosed as exceptional income during the quarter ended June 30, 2012.

   The Company has transferred on December 7, 2012, its 100% ownership in the wholly owned subsidiary, Pfizer Animal Pharma Private Limited to Pfizer Animal Health India Limited, a 100% indirect subsidiary of Pfizer Inc. for a consideration of ₹47,160 lakhs. The gain on sale of investment of ₹3,160 lakhs was disclosed as exceptional income during the quarter ended December 31, 2012.

   Assets, liabilities revenue and expenses for the year ended March 31, 2013 and March 31, 2012 pertain following amounts relating to discontinuing operations:

Total Assets	-	6,439
Total Liabilities	-	2,453

   Profit after tax attributable to discontinuing operations of the Company has been calculated using the effective tax rate of the Company.

5. In view of the transfer of animal health division, the Company now has only one reportable segment 'Pharmaceuticals'. Accordingly, the general and administrative expenses have been allocated to pharmaceuticals segment. As a result, the segmental reporting is not comparable with previous year quarter and year end.

6. The Board of Directors of the Company has recommended a normal dividend of ₹12.50 per equity

8. Figures for previous quarters / year have been regrouped where necessary.

For Pfizer Limited

Aijaz Tobaccowalla
Managing Director

Mumbai, May 14, 2013

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(₹ in lakhs)

	Particulars	As at 31 March, 2013	As at 31 March, 2012
		Audited	Audited
A	EQUITY AND LIABILITIES		
	(a) Other long-term liabilities	--	
	(b) Long-term provisions	1,407	2,583
	sub-total- Non-current liabilities	**1,417**	**2,583**
3	**Current liabilities**		
	(a) Trade payables	15,061	13,604
	(b) Other current liabilities	3,956	3,564
	(c)Short-term provisions	16,075	7,936
	sub-total- Current liabilities	**35,092**	**25,104**
	TOTAL- EQUITY AND LIABILITIES	**205,951**	**158,156**
B	**ASSETS**		
1	**Non-current assets**		
	(a) Fixed assets	2,594	3,186
	(b) Non current investments	4,599	4,750
	(c) Deferred tax assets (net)	3,988	3,708
	(d) Long-term loans and advances	14,331	13,431
	sub-total- Non-current assets	**25,512**	**25,075**
2	**Current assets**		
	(a) Current investments	-	5
	(b) Inventories	16,515	18,324
	(c) Trade receivables	14,209	14,178
	(d) Cash and bank balance	143,294	86,627
	(e) Short-term loans and advances	4,323	12,983
	(f) Other current assets	2,098	964
	sub-total- current assets	**180,439**	**133,081**
	TOTAL- ASSETS	**205,951**	**158,156**